NCT04867434View on ClinicalTrials.gov

Efficacy and Safety of RZL-012 on Submental Fat Reduction

PHASE2CompletedINTERVENTIONAL

Enrollment

151

Participants

Timeline

Start Date

June 15, 2021

Primary Completion Date

April 20, 2022

Study Completion Date

May 31, 2022

Conditions

Submental Fat

Interventions

DRUG

RZL-012

small synthetic molecule for submental fat reduction

DRUG

Placebo

Placebo

Trial Locations (1)

60611

DenovaResearch, Chicago

All Listed Sponsors

lead

Raziel Therapeutics Ltd.

INDUSTRY